where it is stated that the algorithm emphasises the 'achievement and maintenance of near normoglycaemia (HbA 1c <7.0%)', it seems that the therapeutic suggestions, particularly, but not only, for insulin therapy, are not in line with this goal [3, 4] . Almost all the studies comparing the two approaches have shown that targeting postprandial hyperglycaemia is superior to targeting fasting glycaemia in terms of reaching this goal, using insulin or other treatments [3, 4] . Is it possible that not one patient would benefit from receiving prandial insulin therapy instead of a long-acting insulin during an early phase of the disease? Particularly considering that, during the early stage of the disease, the loss of the first phase of insulin secretion, producing high levels of glycaemia after meals [3] , is the key feature of the disease? Certainly, the authors can claim that this strategy is associated with a higher incidence of hypoglycaemia, but, looking at two main trials, INITIATE and 4T [5, 6] , is it clinically relevant that, in order to reach a better HbA 1c level, some patients have to suffer an episode of hypoglycaemia every 1 to 2 months instead of every 4 months?
Finally, in the summary it is also stated that 'rapid addition of medication […]', consistent with the evidence that 'lower levels of glycaemia at the time of initial therapy are associated with lower HbA 1c levels over time and decreased long-term complications'. This is also the rationale for immediately initiating metformin treatment, without waiting for the possible effect of lifestyle intervention. However, examination of this point with respect to adjustment of insulin therapy reveals, to our surprise, that clinicians would need to wait more than 6 months before adjusting the therapy. Which, therefore, is the best way of determining therapeutic options?!
